Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.57 |
| ▸ | USP30 | Q70CQ3 | 6/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.46 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.46 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL189361 | 1.00 | EPHX1 (0.57) | EPHX1USP30ALDH1A1HSD11B1CYP2C9 | |
| SCHEMBL2500606 | 1.00 | EPHX1 (0.57) | EPHX1USP30ALDH1A1HSD11B1CYP2C9 | |
| Hydrochloric Acid SCHEMBL2500609 | 0.98 | EPHX1 (0.56) | EPHX1USP30ALDH1A1HSD11B1CYP2C9 | |
| Hydrochloric Acid SCHEMBL2495441 | 0.98 | EPHX1 (0.56) | EPHX1USP30ALDH1A1HSD11B1CYP2C9 | |
| SCHEMBL2026360 | 0.90 | EPHX1 (0.55) | EPHX1USP30ALDH1A1HSD11B1CYP2C9 | |
| SCHEMBL556321 | 0.90 | EPHX1 (0.55) | EPHX1USP30ALDH1A1HSD11B1CYP2C9 | |
| SCHEMBL2024838 | 0.90 | EPHX1 (0.55) | EPHX1USP30ALDH1A1HSD11B1CYP2C9 | |
| SCHEMBL215297 | 0.90 | EPHX1 (0.65) | EPHX1ALDH1A1MAPTNPC1MAPK1 | |
| SCHEMBL2069710 | 0.89 | EPHX1 (0.57) | EPHX1USP30ALDH1A1HSD11B1CYP2C9 | |
| SCHEMBL6758420 | 0.89 | EPHX1 (0.57) | EPHX1USP30ALDH1A1HSD11B1CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 226 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12637426-B2 | 1-cyano-pyrrolidine compounds as USP30 inhibitors | MISSION THERAPEUTICS LIMITED (GB) | 2026-05-26 | — | — | US | disclosed |
| WO-2026085629-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS, COMPOSITIONS COMPRISING THEM AND USES THEREOF | Université de Montréal (CA) | 2026-04-30 | — | — | WO | disclosed |
| US-12528818-B2 | Compositions and methods for inhibition of RAS | LEIDOS BIOMEDICAL RESEARCH, INC. (US) | 2026-01-20 | — | — | US | disclosed |
| EP-4674484-A2 | THIENOPYRROLE COMPOUNDS | Gilead Sciences, Inc. (US) | 2026-01-07 | — | — | EP | disclosed |
| EP-4665458-A1 | INHIBITING ALPHA V BETA8 INTEGRIN | Morphic Therapeutic, Inc. (US) | 2025-12-24 | — | — | EP | disclosed |
| EP-4139299-B1 | KRAS G12D PROTEIN INHIBITORS | TAIHO PHARMACEUTICAL CO LTD (JP) | 2025-12-17 | — | — | EP | disclosed |
| US-12479834-B2 | Phenol compound or salt thereof | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2025-11-25 | — | — | US | disclosed |
| US-20250340548-A1 | KRAS G12C INHIBITORS | FRONTIER MEDICINES CORP (US) | 2025-11-06 | — | — | US | disclosed |
| EP-4291562-B1 | THIENOPYRROLE COMPOUNDS | GILEAD SCIENCES INC (US) | 2025-09-10 | — | — | EP | disclosed |
| US-20250270206-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF RAS | NNSA | 2025-08-28 | — | — | US | disclosed |
| US-8030501-B2 | Process for producing optically active 3-amino nitrogen-containing compounds | KANEKA CORPORATION (JP) | 2011-10-04 | — | — | US | disclosed |
| US-20100286126-A1 | Organic Compounds | NOVARTIS AG (CH) | 2010-11-11 | — | — | US | disclosed |
| US-20100286126-A1 | Organic Compounds | NOVARTIS AG (CH) | 2010-11-11 | — | — | US | disclosed |
| US-20100069353-A1 | INHIBITORS OF HIV REPLICATION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-03-18 | — | — | US | disclosed |
| US-20090326246-A1 | Method for Production of Optically Active 3-Amino-Nitrogenated Compound | KANEKA CORPORATION (JP) | 2009-12-31 | — | — | US | disclosed |
| EP-2050735-A1 | METHOD FOR PRODUCTION OF OPTICALLY ACTIVE 3-AMINO-NITROGENATED COMPOUND | Kaneka Corporation (JP) | 2009-04-22 | — | — | EP | disclosed |
| US-20050176738-A1 | Melanin-concentrating hormone receptor antagonists and compositions and methods related thereto | NEUROCRINE BIOSCIENCES, INC. (US) | 2005-08-11 | — | — | US | disclosed |
| US-20040147545-A1 | Derivatives of oxazolidinones as antibacterial agents | LABORATORIOS VITA, S.A. (ES) | 2004-07-29 | — | — | US | disclosed |
| US-6140347-A | Azetidine, pyrrolidine and piperidine derivatives as 5-HT receptor agonists | MERCK SHARP & DOHME LTD. (GB) | 2000-10-31 | — | — | US | disclosed |
| WO-1997042189-A1 | AZETIDINE, PYRROLIDINE AND PIPERIDINE DERIVATIVES AS 5-HT RECEPTOR AGONISTS | MERCK SHARP & DOHME LIMITED (GB) | 1997-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286126-A1 | Organic Compounds | CYP3A43, SLCO1B3, CYP2C19 | EPHX1 2576/4885USP30 3965/4885ALDH1A1 166/4885 |
| US-20100069353-A1 | INHIBITORS OF HIV REPLICATION | RTF2, REV1, CCNT1 | EPHX1 2338/4885USP30 3037/4885ALDH1A1 3455/4885 |
| US-20050176738-A1 | Melanin-concentrating hormone receptor antagonists and compositions and methods related thereto | MCHR1, MCHR2, MC1R | EPHX1 515/4885USP30 1859/4885ALDH1A1 1368/4885 |
| US-20090326246-A1 | Method for Production of Optically Active 3-Amino-Nitrogenated Compound | PNMT, NPEPPS, GNMT | EPHX1 4188/4885USP30 2669/4885ALDH1A1 2273/4885 |
| US-20250340548-A1 | KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | EPHX1 1898/4885USP30 1382/4885ALDH1A1 3319/4885 |
| US-20250270206-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF RAS | KRAS, NRAS, HRAS | EPHX1 662/4885USP30 1335/4885ALDH1A1 3201/4885 |
| US-12637426-B2 | 1-cyano-pyrrolidine compounds as USP30 inhibitors | USP30, USP1, USP10 | EPHX1 3856/4885USP30 1/4885ALDH1A1 1185/4885 |
| US-12479834-B2 | Phenol compound or salt thereof | REN, MLX, MYB | EPHX1 948/4885USP30 3423/4885ALDH1A1 287/4885 |
| US-12528818-B2 | Compositions and methods for inhibition of RAS | KRAS, NRAS, HRAS | EPHX1 1925/4885USP30 1723/4885ALDH1A1 2644/4885 |
| US-20040147545-A1 | Derivatives of oxazolidinones as antibacterial agents | OXA1L, Q6ZSR9, PGC | EPHX1 2356/4885USP30 4108/4885ALDH1A1 1970/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.